Published in final edited form as:

Org Lett. 2012 November 2; 14(21): 5574–5577. doi:10.1021/ol302693u.

An Aza-Prins Cyclization Approach to Functionalized Indolizidines from 2-Allylpyrrolidines

Xiaoxi Liu, Michael P. McCormack, and Stephen P. Waters*

Department of Chemistry, The University of Vermont, 82 University Place, Burlington, VT 05405

Abstract

The stereoselective synthesis of a diverse set of functionalized indolizidine systems has been accomplished through the aza-Prins cyclization of 2-allylpyrrolidines. The condensation of aldehydes onto 2-allylpyrrolidines yields iminium ions that undergo highly diastereoselective aza-Prins cyclization, producing up to two stereogenic centers and two new rings in one step.

The indolizidine scaffold is prevalent in a variety of structurally complex, biologically active natural products.¹ Examples of such alkaloids include castanospermine (**1**, Figure 1) and swainsonine (**2**), known for their ability to inhibit glycosidase.² The *Securinega* indolizidine alkaloids securinine (**3**) and phyllanthine (**4**) have been shown to possess antitumor, antimalarial, antibacterial properties³ as well as central nervous system activity as GABA receptor antagonists.⁴ The therapeutic potential of these alkaloids has prompted organic chemists to investigate more concise and stereoselective methods for their construction.⁵

Our laboratory has developed a domino 2-aza-Cope-[3+2]-dipolar cycloaddition protocol for the preparation of functionalized 2-allylpyrrolidine rings (Scheme 1).⁶ In this sequence, the condensation of a homoallylic amine (cf. **5**, Scheme 1) with ethyl glyoxylate affords an imine of type **I**, which after facile 2-aza-Cope rearrangement delivers an azomethine ylide precursor of type **II**. Addition of AgOAc and Et₃N furnishes a stabilized, *N*-metallated azomethine ylide, which in the presence of a dipolarophile (**6**) undergoes subsequent [3+2] dipolar cycloaddition to afford a highly substituted 2-allylpyrrolidine (**7**) in a one-pot process. Up to four stereogenic centers are created within the proline cycloadduct, and the resultant 2-allyl moiety presents a convenient point for additional structural advancements. We are currently investigating the synthetic versatility of the pyrrolidine nitrogen and allylic functions in pyrrolidine **7** as functional points for additional ring-forming events, thereby allowing synthetic chemists to expand the range of *N*-heterocyclic systems obtainable through our method. In this Letter, we report the outcomes of our studies which have enabled a novel route to indolizidine ring systems through the aza-Prins cyclization.

The aza-Prins cyclization has most often been employed as a method to construct piperidine ring systems⁷ and is gaining attention as a tactic in the synthesis of piperidine-containing

Stephen.Waters@uvm.edu.

Supporting Information Available: Experimental procedures, characterization data, and NMR spectra for all new compounds. X-ray crystallographic information for compound **13c'**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

natural products.⁸ However, while applications of the aza-Prins cyclization to give piperidines through iminium⁹ and acyliminium¹⁰ ion ring closures are well-documented, synthetic applications toward the indolizidine ring system are much less developed.¹¹ Although 2-allylpyrrolidine precursors have been used to prepare indolizidines through ring-closing metathesis¹² and nitron cycloaddition¹³ strategies, far fewer examples of their use in aza-Prins or related cationic π -cyclizations have been reported.¹⁴ Drawing upon our ability to access a variety of 2-allylpyrrolidine scaffolds through the 2-aza-Cope-[3+2]-dipolar cycloaddition sequence, we wished to explore the feasibility of preparing indolizidines through the aza-Prins cyclization. Condensation of an aldehyde onto the pyrrolidine nitrogen of **7** (Scheme 2) would furnish an iminium ion (**8**) which could undergo nucleophilic attack by the pendant allyl group. Interception of the developing carbocation by either the solvent or a tethered nucleophile would furnish the six-membered ring of the indolizidine (**9**) and two additional stereocenters. In this manner, the use of tandem, multicomponent reactions would provide access to functionalized indolizidines in a concise and stereoselective fashion.¹⁵

In the early planning stages, we anticipated that the condensation of an aldehyde onto an already sterically encumbered, neopentyl pyrrolidine nitrogen might present a challenge to our synthetic approach. For our initial studies, formaldehyde was chosen as the electrophilic component. Gratifyingly, treatment of 2-allylpyrrolidine **10a** (Scheme 3) with aqueous formaldehyde (10 equiv) and TFA (1.0 equiv) in wet acetonitrile for 24 h at ambient temperature provided indolizidine **11a** in 80% yield as a single observable diastereomer. Aza-Prins cyclizations of 2-allylpyrrolidines **10b** and **10c** under similar conditions gave indolizidines **11b** and **11c** as single diastereomers in 79% and 82% yields, respectively. Conducting these processes in aqueous media promoted clean termination of the aza-Prins reaction through nucleophilic attack by water, affording hydroxy-substituted indolizidines in good overall yields. The high level of diastereoselectivity observed in this cyclization may be attributed to a chair transition state in which the pyrrolidine ring fusions occupy equatorial positions with respect to the newly forming piperidine ring, as well as axial approach of the incoming nucleophile (water) in a favorable anti-periplanar alignment with the π^* orbital of the iminium ion. These stereochemical assignments were confirmed through 2D NMR spectroscopy as well as NOE enhancement studies.

Encouraged by these findings, additional aldehyde components were surveyed. Glyoxylic acid, in the absence of TFA, readily underwent condensation at rt onto the pyrrolidine nitrogen of **10a** (Scheme 4). After olefiniminium ion cyclization, lactone **12a** emerged within 24 h in 94% yield as one diastereomer. The formation of lactone **12a** may be rationalized by ring closure of the olefin in **10a** onto the iminium ion followed by nucleophilic interception of the resulting carbocation by the carboxyl group in glyoxylic acid.¹⁶ In like manner, the reactions of 2-allylpyrrolidines **10b** and **10c** under similar conditions gave indolizidine lactones **12b** and **12c** in good yields (97% and 83%, respectively) as single diastereomers. Spectroscopic analysis of indolizidine **12a** revealed that the newly formed lactone ring in **12a** adopts a *syn*-1,3-diaxial conformation with respect to the indolizidine system. These observations were later confirmed through X-ray analysis and chemical correlation to a related compound, **14b** (vide infra). Overall, the use of glyoxylic acid as the aldehyde component led to the formation of two additional rings and two new stereogenic centers in a single step.

The use of glyoxal as the aldehyde component led to the formation of both indolizidine and lactol ring systems. Treatment of 2-allylpyrrolidines **10a–c** with aqueous glyoxal (10 equiv) and TFA (1.0 equiv) effected complete aza-Prins cyclization within 2–3 h at rt to afford indolizidine products **13a–c** in 66%–73% yield (Scheme 5). These indolizidines were observed to exist in solution as equilibrating mixtures of their corresponding hydroxy-

aldehyde (major) and lactol (minor) forms. In CDCl_3 , the hydroxy-aldehyde forms were predominate in ratios between 2:1 and 7:1 as measured by integration of their ^1H NMR spectra.

Recrystallization of **13c** from $\text{MeOH}:\text{H}_2\text{O}$ (3:2) gave colorless prisms which were revealed by X-ray analysis to be the lactol form (**13c'**, Figure 2). The X-ray crystal structure of **13c'** confirmed that the newly formed six-membered ring of the indolizidine adopts a chair-like conformation, while the two new stereocenters of the lactol function assume a *syn*-1,3-diaxial relationship.

Aza-Prins cyclizations using ethyl glyoxylate (Scheme 6) required somewhat more forcing conditions, presumably due to the increased steric encumbrance of the aldehyde component. A variety of reaction parameters were investigated with 2-allylpyrrolidines **10a–c** to identify the optimal conditions. Good conversions to the corresponding indolizidines were best achieved by conducting the reactions at 50°C , as aza-Prins cyclizations were not observed at room temperature. In this manner, treatment of **10a** with ethyl glyoxylate (5.0 equiv) and TFA (2.0 equiv) for 1.5 h delivered indolizidine **14a**, bearing two ester and one alcohol function, in 66% yield. Although this increase in temperature allowed for shorter reaction times, prolonged exposure of the hydroxy-esters **14a–c** to the reactions conditions for more extended times (3–5 h) led to the gradual formation of lactones **12a–c**, presumably through acid-catalyzed, intramolecular transesterification. Therefore, prompt neutralization after consumption of **10a–c** was necessary for good conversions to **14a–c**. That the indolizidines **14a–c** could be transformed to **12a–c** through lactonization indicated a stereochemical correlation between the two systems. Similar to the aza-Prins cyclizations with previous aldehydes, the resulting new stereogenic centers of the indolizidine ring adopt a *syn*-1,3-diaxial relationship.

In summary, we have developed a new and operationally facile method for the synthesis of indolizidines through aza-Prins cyclizations of 2-allylpyrrolidines. Though aza-Prins cyclizations have proven to be effective for the preparation of piperidines, our work now expands the scope of this reaction to include indolizidine scaffolds. We have also demonstrated that 2-allylpyrrolidines, now readily accessible through our domino 2-aza-Cope-[3+2]-dipolar cycloaddition sequence, are useful precursors for the preparation of additional heterocyclic systems. Synthetic applications of the aza-Prins cyclization toward alkaloid natural products bearing indolizidine frameworks are now being investigated.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the University of Vermont (UVM) for financial support. This work was also generously supported by the Vermont Genetics Network through Grant Number P20 RR16462 from the INBRE Program of the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). X-ray facilities at UVM were provided by the NSF (CHE-1039436). We thank Professor Rory Waterman (UVM) for assistance with X-ray analysis, and Mr. Vic Parcell and Dr. Lynn Teesch at the High Resolution Mass Spectrometry Facility at the University of Iowa for obtaining high-resolution mass spectra.

References

1. Lourenco, AM.; Maximo, P.; Ferreira, LM.; Pereira, MMA. Studies in Natural Products Chemistry: Bioactive Natural Products (Part H). Rahman, A., editor. Vol. 27. Elsevier; Amsterdam: 2002. p. 233-298.

2. (a) Takahata, H.; Momose, T. *The Alkaloids, Chemistry and Pharmacology*. Cordell, GA., editor. Vol. 44. Academic Press; San Diego: 1993. p. 228-256. (b) Lourenco, AM.; Maximo, P.; Ferreira, LM.; Perira, MMA. *Studies in Natural Products Chemistry*. Pahman, AU., editor. Vol. 27. Elsevier; Amsterdam: 2002. p. 233-298.
3. Qin S, Liang J, Guo Y. *Helv Chim Acta*. 2009; 92:399–403.
4. (a) Liras S, Davoren JE, Bordner J. *Org Lett*. 2001; 3:703–706. [PubMed: 11259041] (b) Bentler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR, Enna SJ. *J Brain Res*. 1985; 330:135–140.
5. For examples of indolizidine alkaloid syntheses, see: Michael JP. *Nat Prod Rep*. 2004; 21:625–649. [PubMed: 15459758] Michael JP. *Nat Prod Rep*. 2007; 24:191–222. [PubMed: 17268613] Kamal A, Vangala SR. *Tetrahedron*. 2011; 67:1341–1347.
6. McCormack MP, Shalumova T, Tanski JM, Waters SP. *Org Lett*. 2010; 12:3906–3909. [PubMed: 20681608]
7. Dobbs AP, Guesne SJJ, Parker RJ, Skidmore J, Stephenson RA, Hursthouse MB. *Org Biomol Chem*. 2010; 8:1064–1080. [PubMed: 20165797]
8. (a) Ohmiya S, Higashiyama K, Otomasu H, Haginiwa J, Murakoshi I. *Phytochemistry*. 1981; 20:1997–2001. (b) Liu J, Hsung RP, Peters SD. *Org Lett*. 2004; 6:3989–3992. [PubMed: 15496081] (c) Armstrong A, Bhonoah Y, Shanahan SE. *J Org Chem*. 2007; 72:8019–8024. [PubMed: 17867705]
9. (a) Overman LE, Bell KL. *J Am Chem Soc*. 1981; 103:1851–1853. (b) Overman LE, Sharp MJ. *J Am Chem Soc*. 1988; 110:612–614. (c) Lin H, Overman LE, Rabinowitz MH, Sharp MJ, Zablocki J. *J Am Chem Soc*. 1996; 118:9073–9082. (d) Nishimura T, Unni AK, Yokoshima S, Fukuyama T. *J Am Chem Soc*. 2011; 133:418–419. [PubMed: 21155564] (e) Larsen SD, Grieco PA, Fobare WF. *J Am Chem Soc*. 1986; 108:3512–1513.
10. (a) Padwa A, Bur SK. *Tetrahedron*. 2007; 63:5341–5378. [PubMed: 17940591] (b) Esch PM, de Boer RF, Hiemstra H, Boska IM, Speckamp WN. *Tetrahedron*. 1991; 47:4063–4076. (c) Carballo RM, Ramirez MA, Rodriguez ML, Martin VS, Padron JJ. *Org Lett*. 2006; 8:3837–3840. [PubMed: 16898830]
11. Subba Reddy BV, Chaya DM, Yadav JS, Grée R. *Synthesis*. 2012; 44:297–303.
12. (a) Smith AB, Dae-Shik K. *J Org Chem*. 2006; 71:2547–2557. [PubMed: 16555804] (b) Sattely ES, Cortez GA, Moebius DC, Schrock RR, Hoveyda AH. *J Am Chem Soc*. 2005; 127:8526–8533. [PubMed: 15941288] (c) Park SH, Kang HJ, Ko S, Park S, Chang S. *Tetrahedron: Asymmetry*. 2001; 12:2621–2624.
13. Manzoni L, Arosio D, Belvisi L, Bracci A, Colombo M, Invernizzi D, Scolastico C. *J Org Chem*. 2005; 70:4124–4132. [PubMed: 15876105]
14. For a limited, early example, see: Esch PM, Boska IM, Hiemstra H, de Boer RF, Speckamp WN. *Tetrahedron*. 1991; 47:4039–4062.
15. For selected examples of multicomponent strategies towards indolizidines, see: Lapointe G, Schenk K, Renaud P. *Chem–Eur J*. 2011; 17:3207–3212. [PubMed: 21308816] Coldham I, Jana S, Watson L, Martin NG. *Org Biomol Chem*. 2009; 7:1674–1679. [PubMed: 19343256] Chou SP, Chung YC, Chan PA, Chiang SL, Wu CJ. *J Org Chem*. 2011; 76:692–695. [PubMed: 21162589]
16. Hays SJ, Malone TC, Johnson G. *J Org Chem*. 1991; 56:4084–4086.

Figure 1.
Biologically active indolizidine natural products

Figure 2.
X-ray crystal structure of lactol **13c'**

Scheme 1.

The 2-aza-Cope-[3+2] dipolar cycloaddition route to functionalized 2-allylpyrrolidines

Scheme 2.

Synthesis of indolizidines through aza-Prins cyclization of 2-allylpyrrolidines

Scheme 3.
Aza-Prins cyclizations of 2-allylpyrrolidines with formaldehyde

Scheme 4.

Aza-Prins cyclizations of 2-allylpyrrolidines with glyoxylic acid

Scheme 5.

Aza-Prins cyclizations of 2-allylpyrrolidines with glyoxal

Scheme 6.

Aza-Prins cyclizations of 2-allylpyrrolidines with ethyl glyoxylate